Last reviewed · How we verify
Seqirus Quadrivalent Inactivated Influenza Vaccine
This vaccine induces an immune response against multiple influenza strains.
This vaccine induces an immune response against multiple influenza strains. Used for Prevention of influenza disease caused by four different strains of the influenza virus.
At a glance
| Generic name | Seqirus Quadrivalent Inactivated Influenza Vaccine |
|---|---|
| Also known as | Seqirus QIV |
| Sponsor | Seqirus |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The quadrivalent inactivated influenza vaccine contains inactivated viruses from four different influenza strains, which are used to stimulate the body's immune system to produce antibodies against these strains. This immune response helps to protect against influenza infection.
Approved indications
- Prevention of influenza disease caused by four different strains of the influenza virus
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP (PHASE3)
- Efficacy Study With QIVc in Pediatric Subjects (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age. (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: